December 10, 2019 10:09pm

Who are next, pipelines needed?

Pre-open indications: 3 HITs <BLUE +$9.09, FATE -$0.21 and EDIT +$0.37> and 0 MISS

Share pricing inclines after yesterday’s session declines

It’s not hard to be right so often, it’s about refining expectation, defining insight and trusting your “gut” versus the machines or algorithms

 

My track in writing is separating actionable numbers or intelligence and news into a short-term investment thesis to tackle the “unknown unknowns”

 

The Dow closed DOWN -27.88 points (-0.10%), the S&P closed DOWN -3.44 points (-0.11%) and the NASDAQ closed DOWN -5.64 points (-0.07%)

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday the IBB closed up +0.69% while the XBI closed up +1%
  • Monday the IBB closed down -0.62% while the XBI closed up +0.10%
  • Friday the IBB closed up +1.17% while the XBI closed up +1.15%

 

The advance/decline line scenario of 45 covered companies:

  • Tuesday the close was positive with an A/D line of 22/17, 2 flats, 1 reversed merged (HSGX), 1 dropped (BTX) and 2 acquired;
  • Monday the close was negative with an A/D line of 9/31, 1 flat, 1 reversed merged (HSGX), 1 dropped (BTX) and 2 acquired;
  • Friday the close was positive with an A/D line of 29/9, 3 flats, 1 reversed merged (HSGX), 1 dropped (BTX) and 2 acquired;

 

Henry’omics:

Sector equities jumped on acquisition speculation as indexes dipped on Tuesday as a looming U.S.-China trade deadline dampened investor sentiment.

The month’s upside and downslide are based on China and the U.S. having until Sunday to strike a “phase one” trade deal. If an agreement wasn’t reached by then, new U.S. tariffs will take effect.

 “Why is it that “barely anyone or some investors” – a slight but not great exaggeration – believes in the indications method, despite its demonstrably good record in these and other crises which have threatened our sector interests?

Can the reluctance to believe be in part from the lack of understanding of the nature of indications analysis or the lack of experience with “real” warning problems?”

An indication can be a development of almost any kind. Specifically, it may be a confirmed fact, a possible fact, or an absence of “something”, a fragment of information or even an observation.

The sole provision is that it provides insight to provide some vision into a likely course of action.

 

Think like traders ...

 

Decliners:

  • ReNeuron (RENE.L -$11.00 after Monday’s -$3.50, Friday’s +$14.92, Thursday -$2.00 and last Wednesday’s -$6.00);
  • Sangamo therapeutics (SGMO -$1.26);
  • Regenxbio (RGNX -$0.95);
  • MiMedx (MDXG -$0.60);
  • Fate Therapeutics (FATE -$0.41 after Monday’s +$5.65);

Incliners:

  • bluebird bio (BLUE +$9.09);
  • uniQure NV (QURE +$1.99 after Monday’s -$3.05 and Friday’s +$1.47);
  • Homology Medicine FIXX +$1.00);
  • Ultragenyx (RARE +$0.97);
  • Global Blood Therapeutics (GBT +$0.84 after Monday’s -$4.24, Friday’s +$3.20, Thursday’s +$1.97 and last Wednesday’s +$1.69);

 

The percentage (%) indicators:

  • Tuesday’s range of the 22 upside was +0.% () to +% () while the 17 downside ranged from -0.51% (BLCM) to -12.17% (SGMO); 
  • Monday’s range of the 9 upside was +0.12% (BOLD) to +41.33% (FATE) while the 31 downside ranged from -0.12% (ONVO) to -11.58% (SGMO); 
  • Friday’s range of the 29 upside was +0.07% (BOLD) to +11.66% (RENE.L) while the 9 downside ranged from -0.20% (BMRN) to -3.68% (AGTC); 

 

Upside volume stats:  to compare

  • Tuesday: 10 out of the 22 upside had higher than the 3 month average volume;
  • Monday: 3 out of the 9 upside had higher than the 3 month average volume;
  • Friday: 7 out of the 29 upside had higher than the 3 month average volume;

Downside volume stats:

  • Tuesday: 6 out of the 17 downside had higher than the 3 month average volume;
  • Monday: 13 out of the 31 downside had higher than the 3 month average volume;
  • Friday: 5 out of the 9 downside had higher than the 3 month average volume;

 

2 flat – AGTC and BCLI with 1 reverse merged (HSGX), 1 dropped (BTX), 2 acquired (AST & OSIR) and Spark Therapeutics’ (ONCE) acquisition by Roche could be soon according to rumors from FTC by year’s end.

 

December’s sessions:

Tuesday closed POSITIVE with 17 decliners, 22 advancers, 2 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with 31 decliners, 9 advancers, 1 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 9 decliners, 29 advancers, 3 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed NEGATIVE with 31 decliners, 9 advancers, 1 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed POSITIVE with 13 decliners, 25 advancers, 4 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed POSITIVE with 12 decliners, 25 advancers, 4 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with 26 decliners, 19 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.